Nasopharyngeal Carcinoma Clinical Trials

• Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III);

• All genders，range from 18～65 years old;

• Karnofsky performance status(KPS) ≥ 80;

• Clinical stage III\

⁃ IVa(AJCC/UICC 8th);

• Without significant digestive system disease，nutritional and metabolic diseases or endocrine disease

• Without significant cardiac，respiratory，kidney or liver disease;

• Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy);

• White blood cell(WBC) count ≥ 4×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, Hemoglobin(HGB) ≥ 9g/L, platelet(PLT) count ≥ 100×109/L

• Total bilirubin(TBIL)、alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \< 2.5×upper limit of normal(ULN);

• Adequate renal function: BUN/CRE ≤ 1.5×ULN or endogenous creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula);

• No contraindications to chemotherapy or radiotherapy;

• Inform consent form;